![]() ![]() All rights reserved.Ĭopyright © 2013 - 2022, the American Hospital Association, Chicago, Illinois. The AMA assumes no liability for data contained or not contained herein.Ĭurrent Dental Terminology © 2021 American Dental Association. ![]() The AMA does not directly or indirectly practice medicine or dispense medical services. Applicable FARS/HHSARS apply.įee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not Dosage reduction is recommended in patients known to be poor CYP2D6 metabolizers these patients have higher concentrations of WAKIX than normal CYP2D6 metabolizers.Wisconsin Physicians Service Insurance CorporationĪMA CPT / ADA CDT / AHA NUBC Copyright StatementĬPT codes, descriptions and other data only are copyright 2021 American Medical Association.Dosage adjustment of WAKIX is recommended in patients with moderate or severe renal impairment. WAKIX is not recommended in patients with end-stage renal disease.Dosage adjustment is required in patients with moderate hepatic impairment. WAKIX is contraindicated in patients with severe hepatic impairment. WAKIX is extensively metabolized by the liver.The safety and effectiveness of WAKIX have not been established in patients less than 18 years of age.To enroll or obtain information from the registry, patients can call 1-80. Patients should be encouraged to enroll in the WAKIX pregnancy registry if they become pregnant. There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to WAKIX during pregnancy.Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with WAKIX and for at least 21 days after discontinuing treatment. WAKIX may reduce the effectiveness of hormonal contraceptives.The effectiveness of hormonal contraceptives may be reduced when used with WAKIX and effectiveness may be reduced for 21 days after discontinuation of therapy. Therefore, reduced effectiveness of sensitive CYP3A4 substrates may occur when used concomitantly with WAKIX. WAKIX is a borderline/weak inducer of CYP3A4.Patients should avoid centrally acting H 1 receptor antagonists. H 1 receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of WAKIX. Icd 10 code for narcolepsy without cataplexy full#Dosage adjustments may be required (see full prescribing information).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |